A new inhaled therapy targeting lung inflammation shows promise in reducing damage and improving recovery after severe ...
NTU Singapore is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology ...
University of Colorado Denver Biomedical Engineering Associate Professor Chelsea Magin is developing a lung model to help ...
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which ...
Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy ...
Stocktwits on MSN
TRVI stock’s five-day rally pushes it to an all-time high – here’s what’s happening
Underwriters were given a 30-day option to purchase up to 1.74 million additional shares. ・Trevi is currently developing Haduvio, its treatment for chronic cough in patients with idiopathic pulmonary ...
Nanyang Technological University, Singapore (NTU Singapore) is working with China's Southern University of Science and Technology (SUSTech) and Swedish biotechnology company Lipigon Pharmaceuticals AB ...
Deupirfenidone slowed the progression of lung disease over 26 weeks in patients with idiopathic pulmonary fibrosis in a clinical trial.
Nanyang Technological University, Singapore (NTU Singapore) is working with China’s Southern University of Science and ...
Isolated antineutrophil cytoplasmic antibody-associated interstitial lung disease is an increasingly recognized fibrotic ILD phenotype.
A new inhaled therapy targets ANGPTL4 to reduce lung inflammation, fluid buildup, and scarring after infections. Preclinical ...
Damien Chua, PhD student; Liu Yu Xuan, Research Associate; Joseph Kim, PhD student; Cheng Hong Sheng, Senior Research Fellow; and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results